Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RS-0139 in Recurrent or Metastatic Solid Tumors
NCT04261413Phase 1Completed
- Sponsor
- RS Research
- Start
- Dec 2021
- Primary completion
- Mar 2026
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RS-0139 in solid tumor, sponsored by RS Research. Primary endpoints: Dose-limiting toxicities at 21 days and Adverse Events at 21 days. Started Dec 2021; status: completed.
02
Drugs
RS-0139
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04261413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04261413.